Drug updated on 9/4/2024
Dosage Form | Tablet (oral: 250 mg) |
Drug Class | tryptophan hydroxylase Inhibitors |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.
Latest News
Summary
- Xermelo (telotristat ethyl) is indicated for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.
- This summary is based on the review of two systematic review(s)/meta-analysis(es). [1-2]
- Somatostatin Analogues: Showed symptomatic improvement in 65-72% of patients and a biochemical response in 45-46%.
- Telotristat Ethyl: Reduced bowel movements in 40% of patients with diarrhea refractory to somatostatin analogues, offering a valuable addition for refractory symptoms.
- Liver-directed Therapy: Demonstrated symptom improvement in 82% of patients with liver-dominant disease.
- The interventions, including somatostatin analogues and telotristat ethyl, were generally well tolerated, with few serious treatment-related adverse events reported.
- No significant safety concerns were noted across the reviewed treatments, and the safety profiles were generally favorable.
- There is no population type or subgroup information available in the reviewed studies.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Xermelo (telotristat ethyl) Prescribing Information. | 2022 | Lexicon Pharmaceuticals, Inc., The Woodlands, TX |
Systematic Reviews / Meta-Analyses
Document Title | Year | Source |
---|---|---|
Systemic treatment options for carcinoid syndrome: a systematic review. | 2019 | Oncology |
Management of carcinoid syndrome: a systematic review and meta-analysis. | 2019 | Endocrine-Related Cancer |
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
Carcinoid syndrome: Updates and review of current therapy. | 2019 | Current Treatment Options in Oncology |